Lenvatinib Mesylate

目录号:S5240 批次号:S524005

打印

化学数据

化学结构式 别名 E7080 mesylate 储存条件
(自收到货起)
3年 -20°C 粉状
化学式

C21H19ClN4O4.CH4O3S

分子量 522.96 CAS号 857890-39-2
Solubility (25°C)* 体外 DMSO 13 mg/mL (24.85 mM)
Water Insoluble
Ethanol Insoluble
体内(现配现用)
澄清溶液
10% DMSO 40% PEG 300 5%Tween80 45%ddH2O
1.3mg/ml (2.49mM) 以 1 mL 工作液为例,取100 μL 13mg/ml的澄清DMSO储备液加到400 μL PEG300中,混合均匀使其澄清;向上述体系中加入50 μL Tween80,混合均匀使其澄清;然后继续加入450 μL ddH2O定容至1 mL。工作液请现配现用!
澄清溶液
10%DMSO 90%Corn oil
0.3mg/ml (0.57mM) 以1 mL工作液为例,取100 μL3mg/ml的澄清DMSO储备液加到900 μL玉米油中,混合均匀。工作液请现配现用!
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

制备储备液

生物活性

产品描述 Lenvatinib Mesylate是一种合成、具有口服活性的 tyrosine kinase 的抑制剂,可抑制血管内皮生长因子受体(VEGFR1-3),成纤维细胞生长因子受体(FGFR1-4),血小板衍生生长因子受体(PDGFRα),干细胞因子受体(Kit (c-Kit)),并在转染过程中重新排列(RET (c-RET))。甲磺酸来伐替尼具有潜在的抗肿瘤活性。
靶点
c-RET [2] VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
View More
4.0 nM 5.2 nM 22 nM 39 nM

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

Lenvatinib Mesylate在文献中得到引用

Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma [ Nat Commun, 2024, 15(1):1754] PubMed: 38409200
Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3/4 Ligands in Hepatocellular Carcinoma [ J Hepatocell Carcinoma, 2023, 10:697-712] PubMed: 37138764
Lenvatinib inhibits intrahepatic cholangiocarcinoma via Gadd45a-mediated cell cycle arrest [ Discov Oncol, 2023, 14(1):26] PubMed: 36821012
Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma [ Cancer Res, 2022, canres.2934.2021] PubMed: 35767704
circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis [ Clin Transl Med, 2022, 12(1):e662] PubMed: 35051313
EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli [ Cell Death Dis, 2022, 13(4):351] PubMed: 35428350
Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis [ Sci Rep, 2022, 12(1):12546] PubMed: 35869130
Regorafenib and reactive metabolite of sunitinib activate inflammasomes: Implications for multi tyrosine kinase inhibitor-Iiduced immune related adverse events [ Pharmazie, 2022, 77(2):54-58] PubMed: 35209964
Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report [ Commun Med (Lond), 2022, 2:80] PubMed: 35789568
Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma [ J Immunother Cancer, 2021, 9(6)e002305] PubMed: 34168004

特定的存储和包装每个产品的信息在产品说明书上都有注明。大多数Selleck产品,在推荐的条件下存储可稳定保存两年。产品有时建议的储存温度不同,大多数建议储存在-20°C,抑制剂属于化学试剂,可在常温下运输储存两周左右。即使如此,我们保证产品的出货量将保持产品质量的条件下,一般都会放入冰袋。望阁下收到产品后,请按照产品数据表建议适当存储。

如果需要长期保存,请于零下二十度低温保存。禁止用于人体及治疗!

退换货政策

Selleck提供宽松的退换货承诺,努力为您营造最优的购物体验。每个订单Selleck只提供一次退换货服务,为了确保您的权益,请您仔细阅读以下内容:

1. 请在返还样品之前事先与我们取得联系,以确保产品是直接向我们或者当地代理商购买的;

2. 自收到货物起七天内,如因运输过程有问题或其他任何问题,您可以提出退换货要求;自收到货物起365天内,如因产品质量有问题,您可以提出退换货要求。

3. 请使用我们的快递账号进行退换货,您无需为此承担任何费用。

4. 如您已收到由Selleck开具的发票,则办理退货或订单金额发生变更的换货时,请将发票随商品一同返还给Selleck。请您妥善保管发票,如发票丢失,将无法办理退换货手续。

5. 对于合理的退换货要求,我们会在5个工作日内处理完成您的款项退还和新换货物的运输等,请耐心等待。